

Ref: BHL/ STEX 12/ 2025-26

Date: May 27, 2025

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 Scrip Code: 539872	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051 Symbol: BAJAJHCARE
--	---

Dear Sir/Madam,

Sub: Press Release for the Quarter ended March 31, 2025

In terms of regulation 30 of SEBI (LODR) Regulations, 2015, please find attached herewith Press Release for the quarter and year ended March 31, 2025.

Kindly take the same on record.

Thanking you,

Yours faithfully,

**For and on behalf of Board of Directors
of Bajaj Healthcare Limited**

**Monica Tanwar
Company Secretary & Compliance Officer**

Encl: As above



Investor Release

Bajaj Healthcare Limited Achieves Significant Progress in Q4 & FY25

Strong Turnaround in FY25 with Robust Growth Across Segments

Mumbai, 27th May 2025: Bajaj Healthcare Limited, one of the leading manufacturers of APIs, Intermediates and Formulations, announced its audited financial results for the quarter and year ended 31st March 2025.

Key Financial Highlights

Particulars (Rs. Mn)	Q4 FY25	Q4 FY24	Y-o-Y	FY25	FY24	Y-o-Y
Revenue from Operations	1,544.7	1,339.0	15.4%	5,426.0	4,734.2	14.6%
Gross Profit	740.8	566.5	30.8%	2,755.6	2,273.3	21.2%
Gross Margin (%)	44.1%	40.4%		49.0%	47.2%	
EBITDA	253.3	224.9	12.6%	1,018.3	849.5	19.9%
EBITDA Margin (%)	15.1%	16.0%		18.1%	17.6%	
PAT from Cont. Operations	115.9	(320.0)	-	429.3	(143.3)	-
PAT Margin (Cont. Operations)	6.9%	-22.8%		7.6%	-3.0%	
PAT from Disc. Operations	(4.2)	20.8		(34.3)	(694.7)	
Profit for the period	111.8	(299.2)	-	395.0	(837.9)	-
Profit for the period(%)	6.7%	-21.3%		7.0%	-17.4%	

Revenue Breakup

Particulars (Rs. Mn)	Q4 FY25	Q4 FY24	Y-o-Y	FY25	FY24	Y-o-Y
API (Domestic)	893.3	804.3	11.1%	3269.0	3048.8	7.2%
API (Exports)	407.5	354.8	14.9%	1,241.4	1,143.2	8.6%
Formulations	243.8	179.9	35.6%	915.6	542.2	68.9%

Key Updates

- ✓ **Acquired Genrx Pharmaceuticals Pvt. Ltd.** to enhance in-house formulations manufacturing across allopathic, nutraceutical, and natural products — strengthening backward integration, product portfolio, and operational control.
- ✓ The Company has secured CDMO contracts for 30 APIs with UK/EU partners. During FY25, it **received 6 Certificates of Suitability (CEPs)**, enabling **commercial supplies** to begin from **Q1 FY26** in regulated markets.
- ✓ **Centobamate** has received a favorable **SEC recommendation** and is now awaiting final approval from the **DCGI**, expected any time soon, marking a key step toward market introduction of this complex generic.



- ✓ **Magnesium L-Threonate (Magtein)** is slated for **launch next quarter**. With our strong domestic presence and proven execution capabilities, we are well-positioned to maximize its potential in the Indian Market.
- ✓ Successfully **launched Pimavanserin in India** through collaborations with few pharmaceutical companies, becoming one of the early movers in India for this differentiated CNS molecule.
- ✓ The Company has appointed **Mr. Rohan Parekh** as **Chief Financial Officer and KMP**. He is a Chartered Accountant with 14+ years of experience in Corporate Strategy, FP&A, Financial Reporting, Accounts, Audit, and Treasury across companies like Ashv Finance, Home First Finance Company, and Walker Chandiok & Co. LLP.

Commenting on the Results, Mr. Anil Jain – Managing Director said,

“FY25 has been a transformational year for Bajaj Healthcare. We have delivered a strong financial turnaround and regained profitability, reflecting our commitment to operational discipline and long-term value creation. We closed the year with a net profit of ₹395 Mn, a significant swing from losses in the previous year. Gross margin expanded to 49%, supported by a more favorable product mix. EBITDA grew by 20% year-on-year, outpacing revenue growth and reflecting the benefits of improved operating leverage and cost efficiencies.

Despite headwinds in the API segment across the industry, I am proud to share that we achieved approximately 8% year-on-year revenue growth in our overall API business in FY25. Our Formulations segment also delivered exceptional year-on-year revenue growth of 69% during the same period. These gains reflect the strategic realignment of our portfolio and improved utilization across key facilities.

A key development was the acquisition of Genrx Pharmaceuticals Pvt. Ltd., possession of which was taken in April 2025, significantly enhancing our manufacturing infrastructure and enabling future portfolio expansion. From a product innovation standpoint, we continue to build a differentiated pipeline in CNS and wellness categories. The launch of Pimavanserin and the progress of Cenobamate toward final regulatory approval reflect our ability to deliver niche and high-impact therapies in India.

We also made significant headway in expanding our presence in regulated international markets. With new CDMO partnerships and regulatory clearances now in place, we are on track to become a credible outsourcing partner for global pharma. Our exports currently account for 24% of total revenue, and with these new partnerships, we aim to substantially increase our export share going forward.

We enter FY26 with renewed momentum, a differentiated pipeline, and scalable capacity across APIs, formulations, and CDMO. We are committed to building Bajaj Healthcare into a trusted global pharmaceutical partner through innovation, regulatory strength, and operational excellence.”



About Bajaj Healthcare Ltd:

Bajaj Healthcare Limited a leading Manufacturer of APIs, Intermediates and Formulations. Established in the year 1993. It specializes in manufacturing of intermediates, API, formulations & Nutraceuticals. The Company has state-of-art manufacturing facilities of APIs, intermediates and formulations. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Middle East and South America.

Contact Details:

Bajaj Healthcare Ltd	Investor Relations: MUFG Intime India Pvt. Ltd.
CIN: L99999MH1993PLC072892	Name: Ms. Prachi Ambre/ Mr. Irfan Raeen
Name: Mr. Anil Jain, MD	Email: prachi.ambre@in.mpms.mufg.com / irfan.raeen@in.mpms.mufg.com
Email: investors@bajajhealth.com	Meeting Request Link – Click Here

Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.